Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Immunovant, Inc. (IMVT)
|
Add to portfolio |
|
|
Price: |
$8.38
| | Metrics |
OS: |
130.7
|
M
| |
|
|
Market cap: |
$1.1
|
B
| |
|
|
Net cash:
|
$330
|
M
| |
$2.53
|
per share
|
EV:
|
$765
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
|
| |
|
|
EBIT
|
|
| |
|
|
EPS |
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 |
Revenues | 0.0 | 0.0 | 0.0 | 0.0 |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 0.0 | 0.0 | 0.0 | 0.0 |
Research and development | 101.8 | 68.6 | 47.9 | 25.7 |
General and administrative | 54.2 | 39.5 | 18.2 | 2.7 |
EBIT | -156.0 | -108.1 | -66.1 | -28.4 |
Pre-tax income | -156.8 | -107.8 | -66.3 | -28.6 |
Income taxes | -0.1 | -0.4 | 0.1 | 0.0 |
Tax rate | 0.1% | 0.3% | | |
Net income | -156.7 | -107.4 | -66.4 | -28.6 |
|
Diluted EPS | ($1.43) | ($1.22) | ($1.54) | ($1.29) |
Shares outstanding (diluted) | 109.7 | 87.8 | 43.2 | 22.2 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|